Skip to main content
Equibles
TECH logo

TECH · BIO-TECHNE Corp · Webcasts, Transcripts & Audio

Track TECH — free

Use TECH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TECH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$72.55 -0.07 (-0.10%) At close · Oct 23
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$11.38B
Shares
156.82M
Volume · Oct 23 1.9M Avg daily vol (3M) 3.03M

BIO-TECHNE Corp Webcasts

Earnings calls, investor updates, investor days and conferences for BIO-TECHNE Corp (TECH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q4
2026-08-12
BIO-TECHNE Corp (TECH) Q4 2026 Earnings Call
Revenue
$321.19M*
▲ 1.3% YoY
Gross margin
65.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-05-12
BIO-TECHNE Corp (TECH) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-05-06
BIO-TECHNE Corp (TECH) Q3 2026 Earnings Call Transcript
Positive tone Cell therapy and GMP proteins Spatial biology and Comet platform China and Asia end market
Revenue
$311.42M
▼ 1.5% YoY
Diluted EPS
$0.32
▲ 128.6% YoY
Gross margin
66.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-02-04
BIO-TECHNE Corp (TECH) Q2 2026 Earnings Call Transcript
Positive tone Cell therapy and Fast Track headwind Strategic growth verticals Margin expansion and operating leverage
Revenue
$295.88M
▼ 0.4% YoY
Diluted EPS
$0.24
▲ 9.1% YoY
Gross margin
64.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-11-05
BIO-TECHNE Corp (TECH) Q1 2026 Earnings Call Transcript
Positive tone Cell therapy clinical stage timing / Wilson Wolf Academic end market stabilization Spatial biology and China growth
Revenue
$286.56M
▼ 1% YoY
Diluted EPS
$0.24
▲ 14.3% YoY
Gross margin
65.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-08-06
BIO-TECHNE Corp (TECH) Q4 2025 Earnings Call Transcript
Positive tone Cell and gene therapy franchise China geographic performance Policy and tariff uncertainty
Revenue
$316.96M*
▲ 3.5% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-05-07
BIO-TECHNE Corp (TECH) Q3 2025 Earnings Call Transcript
Positive tone Pharma/biopharma end market recovery Tariffs and macro uncertainty NIH funding and US academic end-market uncertainty
Revenue
$316.18M
▲ 4.2% YoY
Diluted EPS
$0.14
▼ 54.8% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-02-05
BIO-TECHNE Corp (TECH) Q2 2025 Earnings Call Transcript
Confident tone China geographic headwind and outlook Spatial biology and multi-omic capabilities Cell therapy and GMP reagents
Revenue
$297.03M
▲ 9% YoY
Diluted EPS
$0.22
▲ 29.4% YoY
Gross margin
65.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-10-30
BIO-TECHNE Corp (TECH) Q1 2025 Earnings Call Transcript
Positive tone Biopharma end-market stabilization Cell and gene therapy / GMP reagents Spatial biology and molecular diagnostics
Revenue
$289.46M
▲ 4.5% YoY
Diluted EPS
$0.21
▼ 32.3% YoY
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-08-07
BIO-TECHNE Corp (TECH) Q4 2024 Earnings Call Transcript
Positive tone ProteinSimple / instrumentation franchise End market stabilization and recovery Growth verticals outperformance
Revenue
$306.10M*
▲ 1.6% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-05-01
BIO-TECHNE Corp (TECH) Q3 2024 Earnings Call Transcript
Confident tone China end market stabilization Spatial biology / Comet instrument Biopharma / biotech funding environment
Revenue
$303.43M
▲ 3.2% YoY
Diluted EPS
$0.31
▼ 27.9% YoY
Gross margin
67.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-02-01
BIO-TECHNE Corp (TECH) Q2 2024 Earnings Call Transcript
Positive tone China softness and stabilization Lunaphore acquisition and M&A pipeline CEO leadership transition
Revenue
$272.60M
▲ 0.4% YoY
Diluted EPS
$0.17
▼ 45.2% YoY
Gross margin
64.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-10-31
BIO-TECHNE Corp (TECH) Q1 2024 Earnings Call Transcript
Revenue
$276.94M
▲ 2.7% YoY
Diluted EPS
$0.31
▼ 43.6% YoY
Gross margin
66.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-08-08
BIO-TECHNE Corp (TECH) Q4 2023 Earnings Call Transcript
Revenue
$301.32M*
▲ 4.5% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-05-03
BIO-TECHNE Corp (TECH) Q3 2023 Earnings Call Transcript
Revenue
$294.15M
▲ 1.3% YoY
Diluted EPS
$0.43
▲ 16.2% YoY
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-02-02
BIO-TECHNE Corp (TECH) Q2 2023 Earnings Call Transcript
Revenue
$271.58M
▲ 0.9% YoY
Diluted EPS
$0.31
▼ 36.7% YoY
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-11-01
BIO-TECHNE Corp (TECH) Q1 2023 Earnings Call Transcript
Revenue
$269.65M
▲ 4.6% YoY
Diluted EPS
$0.55
▲ 30.2% YoY
Gross margin
66.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-08-04
BIO-TECHNE Corp (TECH) Q4 2022 Earnings Call Transcript
Revenue
$288.23M*
▲ 11.3% YoY
Gross margin
69.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-05-04
BIO-TECHNE Corp (TECH) Q3 2022 Earnings Call Transcript
Revenue
$290.38M
▲ 19.2% YoY
Diluted EPS
$0.37
▲ 32.1% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-02-01
BIO-TECHNE Corp (TECH) Q2 2022 Earnings Call Transcript
Revenue
$269.28M
▲ 20.1% YoY
Diluted EPS
$0.49
▲ 70.4% YoY
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-11-02
BIO-TECHNE Corp (TECH) Q1 2022 Earnings Call Transcript
Revenue
$257.72M
▲ 26.2% YoY
Diluted EPS
$0.42
▲ 103.6% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-08-05
BIO-TECHNE Corp (TECH) Q4 2021 Earnings Call Transcript
Revenue
$259.03M*
▲ 47.3% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-05-06
BIO-TECHNE Corp (TECH) Q3 2021 Earnings Call Transcript
Revenue
$243.55M
▲ 25.1% YoY
Diluted EPS
$0.28
▲ 21.7% YoY
Gross margin
69.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-02-02
BIO-TECHNE Corp (TECH) Q2 2021 Earnings Call Transcript
Revenue
$224.25M
▲ 21.3% YoY
Diluted EPS
$0.29
▼ 61.9% YoY
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-11-05
BIO-TECHNE Corp (TECH) Q1 2021 Earnings Call Transcript
Revenue
$204.20M
▲ 11.4% YoY
Diluted EPS
$0.21
▲ 124.3% YoY
Gross margin
67.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-08-04
BIO-TECHNE Corp (TECH) Q4 2020 Earnings Call Transcript
Revenue
$175.83M
▼ 8.3% YoY
Diluted EPS
$0.37
▲ 252.4% YoY
Gross margin
64.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-04-30
BIO-TECHNE Corp (TECH) Q3 2020 Earnings Call Transcript
Revenue
$194.68M
▲ 5.3% YoY
Diluted EPS
$0.23
▼ 20% YoY
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-02-04
BIO-TECHNE Corp (TECH) Q2 2020 Earnings Call Transcript
Revenue
$184.93M
▲ 6% YoY
Diluted EPS
$0.76
▲ 571.1% YoY
Gross margin
65.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-09-30
Date not confirmed
BIO-TECHNE Corp (TECH) Q1 2020 Earnings Call Transcript
Revenue
$183.24M
▲ 12.4% YoY
Diluted EPS
$0.09
▼ 17.8% YoY
Gross margin
64.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–29 of 29 webcasts
Key facts CIK 842023 CUSIP 09073M104 13F (30d) 99 filings 94 filers Visit website Investor relations